This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

Viridian Therapeutics is a part of the model portfolio of the Biotech Forum. We are currently offering a one-month trial into the Biotech Forum at half the regular price. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .When I last wrote about Viridian Therapeutics, Inc. ( NASDAQ: VRDN ) in August, I noted this biopharma had some key catalysts up in front of it. One of those catalysts was disclosed M ...

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.60%. A quarter ago, it was expected that this company would post a loss of $0.87 per share when it actually produced a loss of $1.02, delivering a surprise of -17.24%.Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1187261 (State or other ju ...

Exhibit 99.1 Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data - Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in December 2024 - - Initiated two global phase 3 clinical trials of subcutaneous VRDN-003, REVEAL-1 and REVEAL-2 in August, in active and chronic TED, respectively; topline data anticipated in the first ...

Shares of Viridian Therapeutics, Inc. (VRDN) surged 32.1% on Sept. 10 after the company announced positive top-line data from the phase III THRIVE study, which evaluated its lead pipeline drug, veligrotug (formerly known as VRDN-001) for treating patients with active thyroid eye disease (TED). The THRIVE study met all the primary and all secondary endpoints by demonstrating highly statistically significant improvements in all measured signs and symptoms of TED at week 15 of treatment with veligrotug, an ant ...

FG Trade/E+ via Getty Images The last time I wrote about Viridian Therapeutics, Inc. (VRDN) it was in a Seeking Alpha article entitled "Viridian: Despite Drop, Advancement Towards Phase 3 continues." At that time, I noted that data from the THRIVE phase 3 study using veligrotug [VRDN-001] for the treatment of patients with active thyroid eye disease [TED], would be released around mid-2024. I'm happy to state that the company just released data showing that this drug was able to meet the primary endpoint of ...

Viridian Therapeutics Inc (NASDAQ:VRDN) stock is up 11.1% to trade at $15.75 today, and earlier traded as high as $16.35, after the biotech company's eye disorder treatment met the main goal of a late-stage study. VRDN is on track for its best single-session gain of 2024. Despite today's breakout, the shares are still 28% lower year to date, and momentum has fallen short of its 200- day moving average. A short squeeze could keep the wind at the equity's back though; short interest fell 7.3% in the two most ...

14 August 2024 | 2:40PM EDT Viridian Therapeutics Inc. (VRDN): SC TED Race Heats Up Following SLRN's Prioritization on Lonigutamab On Tuesday 8/13, SLRN (not covered) announced its refocused pipeline strategy prioritizing lonigutamab in thyroid eye disease (TED), discontinuing investments in HS/PsA, and a 33% reduction in force to extend cash runway to mid-2027. Recall that lonigutamab is an SC formulated IGF-1R mAb competing directly with VRDN-003. Early lonigutamab PoC data from 12 patients was disclosed ...